Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug;9(8):643-60.
doi: 10.1038/nrd3184.

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Affiliations
Review

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Klaus Strebhardt. Nat Rev Drug Discov. 2010 Aug.

Abstract

The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of critical cell cycle events. Because PLK1 has been preclinically validated as a cancer target, small-molecule inhibitors of PLK1 have become attractive candidates for anticancer drug development. Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumour suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals. In this article, recent insights into the biology of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-molecule PLK1 inhibitors will be examined.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Oncogene. 2002 Sep 26;21(43):6633-40 - PubMed
    1. Eur J Pharmacol. 2008 Sep 4;591(1-3):102-5 - PubMed
    1. Cancer Res. 2006 Nov 1;66(21):10253-7 - PubMed
    1. Cell Cycle. 2006 Apr;5(8):853-64 - PubMed
    1. Bioorg Med Chem. 2007 Jan 15;15(2):800-14 - PubMed

MeSH terms

LinkOut - more resources